Bristol Myers Squibb's Phase 3 Checkmate -77T Trial Met Its Primary Endpoint Of Improved Event-free Survival In Non-small Cell Lung Cancer, Evaluating Neoadjuvant Opdivo (Nivolumab) With Chemotherapy Followed By Surgery And Adjuvant Opdivo
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb's Phase 3 Checkmate -77T trial has met its primary endpoint of improved event-free survival in non-small cell lung cancer. The trial evaluated the use of neoadjuvant Opdivo (Nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo.
September 22, 2023 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's successful Phase 3 trial could potentially lead to increased revenues from the sale of Opdivo, which could positively impact the company's stock price.
The successful completion of a Phase 3 trial is a significant milestone for any pharmaceutical company. It indicates that the drug is effective and safe for use, which could lead to regulatory approval and commercialization. This could potentially increase the revenues of Bristol Myers Squibb, which would likely have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100